Skip to main content

Table 4 Modulation of MGMT promoter methylation

From: MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

Patient Pre-treatment Post-treatment
  MGMT MGMT CD133 MGMT MGMT CD133
  Promoter    Promoter   
Patient 1 M + ++ M +/− +
Patient 2 M ++ + U ++ +/−
Patient 3 U +++ + U + ++
Patient 4 M ++ + M ++ +
Patient 5 M + ++ U + +
Patient 6 U + + M + +
Patient 7 U + + U + +++
Patient 8 M + ++ U + ++
Patient 9 U +/− + -   -
Patient 10 U +/− + U ++ ++
Patient 11 M ++ + M +++ +
  1. MGMT and CD133 in recurrent GBM before and after treatment with radiotherapy and temozolomide.